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Original Article

Cardiac Myosin Activation with Omecamtiv
Mecarbil in Systolic Heart Failure
J.R. Teerlink, R. Diaz, G.M. Felker, J.J.V. McMurray, M. Metra, S.D. Solomon,
K.F. Adams, I. Anand, A. Arias‑Mendoza, T. Biering‑Sørensen, M. Böhm,
D. Bonderman, J.G.F. Cleland, R. Corbalan, M.G. Crespo‑Leiro, U. Dahlström,
L.E. Echeverria, J.C. Fang, G. Filippatos, C. Fonseca, E. Goncalvesova,
A.R. Goudev, J.G. Howlett, D.E. Lanfear, J. Li, M. Lund, P. Macdonald, V. Mareev,
S. Momomura, E. O’Meara, A. Parkhomenko, P. Ponikowski, F.J.A. Ramires,
P. Serpytis, K. Sliwa, J. Spinar, T.M. Suter, J. Tomcsanyi, H. Vandekerckhove,
D. Vinereanu, A.A. Voors, M.B. Yilmaz, F. Zannad, L. Sharpsten, J.C. Legg,
C. Varin, N. Honarpour, S.A. Abbasi, F.I. Malik, and C.E. Kurtz,
for the GALACTIC-HF Investigators*

A BS T R AC T
BACKGROUND

The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction.
Its effect on cardiovascular outcomes is unknown.
METHODS

We randomly assigned 8256 patients (inpatients and outpatients) with symptomatic chronic heart failure and an ejection fraction of 35% or less to receive
omecamtiv mecarbil (using pharmacokinetic-guided doses of 25 mg, 37.5 mg, or
50 mg twice daily) or placebo, in addition to standard heart-failure therapy. The
primary outcome was a composite of a first heart-failure event (hospitalization or
urgent visit for heart failure) or death from cardiovascular causes.
RESULTS

During a median of 21.8 months, a primary-outcome event occurred in 1523 of
4120 patients (37.0%) in the omecamtiv mecarbil group and in 1607 of 4112 patients (39.1%) in the placebo group (hazard ratio, 0.92; 95% confidence interval
[CI], 0.86 to 0.99; P = 0.03). A total of 808 patients (19.6%) and 798 patients
(19.4%), respectively, died from cardiovascular causes (hazard ratio, 1.01; 95% CI,
0.92 to 1.11). There was no significant difference between groups in the change
from baseline on the Kansas City Cardiomyopathy Questionnaire total symptom
score. At week 24, the change from baseline for the median N-terminal pro–B-type
natriuretic peptide level was 10% lower in the omecamtiv mecarbil group than in
the placebo group; the median cardiac troponin I level was 4 ng per liter higher.
The frequency of cardiac ischemic and ventricular arrhythmia events was similar
in the two groups.

The authors’ full names, academic degrees, and affiliations are listed in the Appendix. Address reprint requests to Dr.
Teerlink at San Francisco Veterans Affairs
Medical Center, Cardiology, 111C, Bldg.
203, Rm. 2A-49, 4150 Clement St., San
Francisco, CA 94121, or at j ohn.teerlink@
ucsf.edu.
*A complete list of GALACTIC-HF committee members and investigators is provided in the Supplementary Appendix,
available at NEJM.org.
This article was published on November
13, 2020, at NEJM.org.
DOI: 10.1056/NEJMoa2025797
Copyright © 2020 Massachusetts Medical Society.

CONCLUSIONS

Among patients with heart failure and a reduced ejection, those who received
omecamtiv mecarbil had a lower incidence of a composite of a heart-failure event
or death from cardiovascular causes than those who received placebo. (Funded by
Amgen and others; GALACTIC-HF ClinicalTrials.gov number, NCT02929329; EudraCT
number, 2016-002299-28.)
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he defining characteristic of
heart failure with a reduced ejection fraction is decreased systolic function leading
to reduced cardiac output and increased filling
pressures. To date, no medications that directly
enhance systolic function have improved outcomes.1 Cardiac myosin activators are a new class
of myotropes2 that improve myocardial function
by directly augmenting cardiac sarcomere function. Omecamtiv mecarbil,3,4 the first of this class,
augments cardiac contractility by selectively binding to cardiac myosin,5 thus increasing the number of force generators (myosin heads) that can
bind to the actin filament and initiate a power
stroke at the start of systole. Short-term intravenous administration of omecamtiv mecarbil improved cardiac performance in early clinical
studies.6-8
In patients with chronic heart failure with a
reduced ejection fraction, the administration of
omecamtiv mecarbil for 20 weeks increased the
left ventricular systolic ejection time and stroke
volume, decreased the left ventricular systolic and
diastolic volumes (which suggested beneficial
reverse cardiac remodeling), and reduced the
plasma natriuretic peptide levels and heart rate.9
On the basis of these findings, we designed and
conducted the randomized, placebo-controlled,
phase 3 Global Approach to Lowering Adverse
Cardiac Outcomes through Improving Contractility in Heart Failure (GALACTIC-HF) trial to assess
whether treatment with omecamtiv mecarbil in
patients with heart failure who had a reduced
ejection fraction would lower the risk of heartfailure events and cardiovascular death.10,11

Me thods
Trial Design and Oversight

The executive committee designed and oversaw
the conduct and analysis of the trial in collaboration with the sponsors, Amgen, Cytokinetics,
and Servier.10 The trial was conducted and reported
in accordance with the protocol and the statistical analysis plan, which are available in the same
document with the full text of this article at
NEJM.org. The trial was approved by the regulatory agencies in the participating countries and
by the institutional review board or ethics committee at each trial center. An independent data
monitoring committee evaluated patient safety.
The executive committee and sponsors partici2
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pated in the trial design and in the selection of
participating centers and interpretation of the data;
Amgen was responsible for site monitoring and
for the collection, storage, and initial analyses
of the data, evaluations that were replicated by
an independent academic statistician (Table S1
in the Supplementary Appendix, available at
NEJM.org). The first author had unrestricted access to the data and drafted the initial version of
the manuscript, which was reviewed and edited
by all the authors, who made the decision to
submit the manuscript for publication. The executive committee vouches for the accuracy and
completeness of the analyses and for the fidelity
of the trial to the protocol.
Patients

Eligibility requirements included an age between
18 and 85 years, along with New York Heart Association functional class II, III, or IV symptoms
and a left ventricular ejection fraction of 35% or
less. The patients were currently hospitalized for
heart failure (inpatients) or had either made an
urgent visit to the emergency department or been
hospitalized for heart failure within 1 year before screening (outpatients). All the patients had
an N-terminal pro–B-type natriuretic peptide
(NT-proBNP) level of 400 pg per milliliter or
more or a BNP level of 125 pg per milliliter or
more; among the patients with atrial fibrillation
or flutter, the cutoff NT-proBNP level was 1200 pg
per milliliter or more and the cutoff BNP level
was 375 pg per milliliter or more. Patients were
required to receive pharmacologic and device
therapy for heart failure in accordance with regional clinical practice guidelines and with
doses optimized according to the investigator’s
judgment.
Key exclusion criteria were current hemodynamic or clinical instability leading to the use of
mechanical support or intravenous medication,
a systolic blood pressure of less than 85 mm Hg,
an estimated glomerular filtration rate (GFR) of
less than 20 ml per minute per 1.73 m2 of bodysurface area, a recent acute coronary syndrome
event or cardiovascular procedure (including a
planned procedure), and other conditions that
would adversely affect participation in the trial.
A full description of the eligibility criteria has
been published previously10 and is available in the
Supplementary Appendix. All the patients provided
written informed consent.
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Table 1. Characteristics of the Patients at Baseline.*
Characteristic
Age — yr
Female sex — no. (%)
Race or ethnic group — no. (%)†
White
Asian
Black
Other
Geographic region — no. (%)
Eastern Europe or Russia
Western Europe, South Africa, or Australasia
Latin America
United States or Canada
Asia
Inpatient setting — no. (%)
Clinical features
Atrial fibrillation or flutter — no. (%)
Type 2 diabetes mellitus — no. (%)
Ischemic heart failure — no. (%)
Left ventricular ejection fraction — %
NYHA classification — no. (%)
II
III
IV
Median total symptom score on KCCQ (IQR)‡
Outpatient
Inpatient
Systolic blood pressure — mm Hg
Heart rate — beats/min
Median NT-proBNP (IQR) — pg/ml
Median cardiac troponin I (IQR) — ng/liter
Median eGFR (IQR) — ml/min/1.73m2
Heart-failure therapy — no. (%)
ACE inhibitor, ARB, or ARN inhibitor
ARN inhibitor
Beta-blocker
Mineralocorticoid-receptor antagonist
SGLT2 inhibitor
Cardiac-resynchronization therapy
Implantable cardioverter–defibrillator

Omecamtiv Mecarbil
(N = 4120)

Placebo
(N = 4112)

64.5±11.3
875 (21.2)

64.5±11.4
874 (21.3)

3196 (77.6)
355 (8.6)
285 (6.9)
284 (6.9)

3201 (77.8)
355 (8.6)
277 (6.7)
279 (6.8)

1344 (32.6)
961 (23.3)
787 (19.1)
693 (16.8)
335 (8.1)
1044 (25.3)

1337 (32.5)
960 (23.3)
787 (19.1)
693 (16.9)
335 (8.1)
1040 (25.3)

1146 (27.8)
1652 (40.1)
2193 (53.2)
26.6±6.3

1099 (26.7)
1657 (40.3)
2222 (54.0)
26.5±6.3

2195 (53.3)
1801 (43.7)
124 (3.0)
68.8 (49.0–87.5)
74.0 (54.2–90.6)
54.2 (34.4–72.9)
116.3±15.4
72.4±12.2
1977 (980–4061)
27 (12–52)
58.8 (44.3–74.3)

2173 (52.8)
1815 (44.1)
124 (3.0)
68.8 (49.0–87.5)
75.0 (56.3–91.7)
52.1 (31.3–69.8)
116.6±15.3
72.3±12.1
2025 (1000–4105)
27 (13–52)
58.7 (43.8–73.7)

3583 (87.0)
819 (19.9)
3881 (94.2)
3199 (77.6)
104 (2.5)
592 (14.4)
1326 (32.2)

3576 (87.0)
782 (19.0)
3883 (94.4)
3198 (77.8)
114 (2.8)
566 (13.8)
1288 (31.3)

*	Plus–minus values are means ±SD. Percentages may not total 100 because of rounding. Additional baseline characteristics are provided in Tables S3 and S4 in the Supplementary Appendix. ACE denotes angiotensin-converting enzyme,
ARB angiotensin-receptor blocker, ARN angiotensin receptor–neprilysin, eGFR estimated glomerular filtration rate, IQR
interquartile range, NT-proBNP N-terminal pro–B-type natriuretic peptide, NYHA New York Heart Association, and
SGLT2 sodium–glucose cotransporter 2.
†	Race or ethnic group was reported by the patients. The category of Other includes American Indian or Alaska Native,
Native Hawaiian or other Pacific Islander, or multiple patient-identified races or ethnic groups.
‡	Scores on the Kansas City Cardiomyopathy Questionnaire (KCCQ) range from 0 to 100, with higher scores indicating a
lower frequency and severity of symptoms.
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Trial Procedures

Primary and Secondary Outcomes

We randomly assigned patients in a 1:1 ratio to
receive either oral omecamtiv mecarbil or placebo
using an interactive Web-response or voice-response
system and a sequestered, fixed randomization
schedule, with balanced blocks within strata
defined according to the randomization setting
(inpatient or outpatient) and geographic region.
The patients were assigned to receive omecamtiv
mecarbil at a dose of 25 mg, 37.5 mg, or 50 mg
twice daily on the basis of plasma levels of the
drug, as described in the Supplementary Appendix. All the patients and investigators were unaware of the plasma levels and the dispensed dose.
Postrandomization assessments were performed
at weeks 2, 4, 6, 8, 12, 24, 36, and 48 and every
16 weeks thereafter (Fig. S1 and Table S2). The
administration of omecamtiv mecarbil or placebo was temporarily suspended if the patient had
clinical signs or symptoms consistent with acute
myocardial infarction or ischemia.

The primary outcome was a composite of a heartfailure event or cardiovascular death, whichever
occurred first, in a time-to-event analysis. A heartfailure event was defined as an urgent clinic
visit, emergency department visit, or hospitalization for subjectively and objectively worsening
heart failure leading to treatment intensification
beyond a change in oral diuretic therapy.12 Secondary outcomes were cardiovascular death, the
change in the total symptom score on the Kansas City Cardiomyopathy Questionnaire (KCCQ)
from baseline to week 24 (on a scale of 0 to 100,
with higher scores indicating a lower frequency
and severity of symptoms), the first heart-failure
hospitalization, and death from any cause. All
deaths, heart-failure events, major cardiac ischemic events (myocardial infarction, hospitalization for unstable angina, and coronary revascularization), and strokes were adjudicated by an
external clinical-events committee at the Duke

Placebo

Omecamtiv mecarbil

A Primary Outcome

B Cardiovascular Death
Hazard ratio, 0.92 (95% CI, 0.86–0.99)
50 P=0.03
45
40
35
30
25
20
15
10
5
0
0
6
12
18
24
30
36

90
80
70
60
50

90

40
30
20
10
0

50
45
40
35
30
25
20
15
10
5
0

100

Cumulative Incidence (%)

100

Cumulative Incidence (%)

of

80
70
60
50

Hazard ratio, 1.01 (95% CI, 0.92–1.11)

6

0

12

18

24

30

36

40
30
20
10

0

6

12

18

24

30

0

36

0

Months since Randomization

12

18

24

30

36

Months since Randomization

No. at Risk

Placebo
4112
Omecamtiv mecarbil 4120

6

No. at Risk

3310
3391

2889
2953

2102
2158

1349
1430

647
700

141
164

Placebo
4112
Omecamtiv mecarbil 4120

3821
3838

3560
3556

2722
2710

1788
1838

885
903

201
224

Figure 1. Primary Composite Outcome.
The primary outcome was a composite of a heart-failure event or cardiovascular death, whichever occurred first. The cumulative incidence of the primary composite outcome (Panel A) and death from cardiovascular causes (Panel B) was estimated with the use of the
Kaplan–Meier method. Hazard ratios and 95% confidence intervals were estimated with the use of Cox regression models stratified according to randomization location and geographic region, with the trial group as an explanatory variable. Analyses were performed in
the intention-to-treat population in the full analysis set. The inset in each panel shows the same data on an enlarged y axis.
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Clinical Research Institute, whose members were
unaware of trial group assignments and used
standardized definitions. (Details are provided in
the Supplementary Appendix.12)
Statistical Analysis

We determined that the enrollment of approximately 8000 patients would provide a power of
90% to detect a hazard ratio of 0.80 for cardiovascular death in the group receiving omecamtiv
mecarbil (Fig. S2). The trial was event driven with
a target of approximately 1590 cardiovascular
deaths. The overall type I error was 0.05 for twosided testing across primary and secondary outcomes. Control for multiple comparisons was
achieved by means of the following testing algo-

rithm: if the primary outcome met the P-value
threshold of 0.05, the alpha error would be divided unequally between cardiovascular death
(96% of the overall alpha error, or 0.048) and the
change from baseline to week 24 in the KCCQ
total symptom score (4% of the overall alpha error, or 0.002).13 On the basis of a one-sided alpha
level of 0.0005, a single interim efficacy analysis
was conducted after approximately two thirds of
the targeted number of cardiovascular deaths
had occurred. Given the negligible effect of this
interim analysis on the final alpha level, the full
alpha error of 0.05 was used in the final analysis,
consistent with the Haybittle–Peto approach.14,15
We performed the efficacy analysis in the full
analysis set of the intention-to-treat population,

Table 2. Primary and Secondary Cardiovascular Outcomes.*

Variable

Omecamtiv Mecarbil
(N = 4120)
Value

Events

Value

no./100
patient-yr
Primary composite outcome — no. (%)‡
Cardiovascular death as first event
Hospitalization for heart failure as first
event
Urgent outpatient visit for heart failure as
first event

1523 (37.0)

24.2

Hazard Ratio or
Difference
(95% CI)†

P Value

26.3

0.92 (0.86 to 0.99)

0.03

10.8

1.01 (0.92 to 1.11)

0.86§

Placebo
(N = 4112)
Events
no./100
patient-yr
1607 (39.1)

346 (8.4)

371 (9.0)

1107 (26.9)

1133 (27.6)

70 (1.7)

103 (2.5)

Secondary outcomes
Cardiovascular death — no. (%)

808 (19.6)

10.9

798 (19.4)

Change in KCCQ total symptom score
at wk 24

0.03§

Inpatients

23.7±0.7

NA

21.2±0.7

NA

2.5 (0.5 to 4.5)

Outpatients

5.8±0.3

NA

6.3±0.3

NA

−0.5 (−1.4 to 0.5)

First hospitalization for heart failure —
no. (%)

1142 (27.7)

18.0

1179 (28.7)

19.1

0.95 (0.87 to 1.03)

NA

Death from any cause — no. (%)

1067 (25.9)

14.4

1065 (25.9)

14.4

1.00 (0.92 to 1.09)

NA

1177 (28.6)

18.7

1236 (30.1)

20.3

0.93 (0.86 to 1.00)

NA

Exploratory outcome
Heart-failure event — no. (%)

*	Plus–minus values are least-squares means ±SE. P values for efficacy outcomes are reported only for outcomes that were included in the
hierarchical-testing strategy. NA denotes not applicable.
†	All listed values are hazard ratios except for the between-group differences in the changes in the total symptom score on the Kansas City
Cardiomyopathy Questionnaire (KCCQ).
‡	The primary outcome was a composite of heart-failure events (hospitalization or unscheduled urgent clinic, office, or emergency department visit resulting in intravenous therapy for heart failure) or death from cardiovascular causes.
§	The between-group difference in this category was not determined to be significant. After the determination of significance for the primary
outcome, cardiovascular death was tested against an alpha of 0.048, and the change from baseline in the KCCQ total symptom score was
tested against an alpha of 0.002 with a joint test for an effect among inpatients and outpatients. (Additional details about the statistical
analysis are provided in the Supplementary Appendix.)
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0.7

0.9 1.0 1.1

Omecamtiv Mecarbil
Better

1.5 1.7

Placebo
Better

1.3

0.93 (0.85–1.03)
0.91 (0.83–1.01)

0.90 (0.82–0.98)
0.96 (0.86–1.07)

0.91 (0.83–1.01)
0.93 (0.84–1.03)

Atrial fibrillation or flutter
No
Yes
LVEF
≤Median (28%)
>Median (28%)
NT−proBNP
Inpatient + ≤median
Inpatient + >median
Outpatient + ≤median
Outpatient + >median
Heart rate
≤Median (71 bpm)
>Median (71 bpm)
Systolic BP distribution
≤Median (116 mm Hg)
>Median (116 mm Hg)
Systolic BP level
<100 mm Hg
≥100 mm Hg
eGFR
≤60 ml/min/1.73 m2
>60 ml/min/1.73 m2
ACE inhibitor therapy
No
Yes
ARB therapy
No
Yes
MRA therapy
No
Yes
ARN inhibitor
No
Yes
Receipt of CRT
No
Yes
Receipt of ICD
No
Yes

Subgroup (cont.)

0.7

0.9 1.0 1.1

Omecamtiv Mecarbil
Better

0.5

1.5 1.7

Placebo
Better

1.3

0.94 (0.86–1.03)
0.88 (0.78–0.98)

0.93 (0.86–1.01)
0.84 (0.72–0.99)

0.91 (0.84–0.99)
0.97 (0.83–1.13)

0.98 (0.85–1.12)
0.91 (0.83–0.98)

0.91 (0.85–0.99)
0.97 (0.83–1.15)
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0.90 (0.81–1.00)

0.98 (0.89–1.07)
0.84 (0.75–0.94)

0.89 (0.76–1.05)
0.92 (0.86–1.00)
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0.95 (0.85–1.05)

0.91 (0.82–1.01)
0.93 (0.85–1.03)

0.97 (0.74–1.28)
0.75 (0.61–0.92)
0.88 (0.73–1.05)
0.85 (0.75–0.97)

0.84 (0.77–0.92)
1.04 (0.94–1.16)

0.86 (0.79–0.94)
1.05 (0.93–1.18)

Hazard Ratio (95% CI)

of

0.97 (0.87–1.08)
0.88 (0.80–0.97)

0.90 (0.76–1.06)
0.93 (0.86–1.00)
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0.88 (0.77–1.02)
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0.85 (0.74–0.99)
0.98 (0.85–1.12)

0.95 (0.81–1.12)
0.92 (0.85–0.99)

0.91 (0.82–1.02)
0.94 (0.86–1.03)

0.80 (0.61–1.05)
0.90 (0.80–1.02)
0.90 (0.75–1.07)
0.85 (0.73–0.99)
1.07 (0.93–1.23)

0.89 (0.78–1.01)
0.94 (0.86–1.02)

0.92 (0.86–0.99)

Hazard Ratio (95% CI)

n e w e ng l a n d j o u r na l

0.5

Overall
Randomization setting
Inpatient
Outpatient
Region
Asia
Eastern Europe or Russia
Latin America
United States and Canada
W. Europe, South Africa, or Australia
Age
<65
≥65
Sex
Female
Male
Baseline weight
≤68.4 kg
>68.4 to ≤80.0 kg
>80.0 to ≤93.9 kg
>93.9 kg
Race
Asian
Black
White
Other
Ethnic group
Hispanic or Latino
Not Hispanic or Latino
NYHA class
II
III or IV
Diabetes
No
Yes
Primary cause of HF
Ischemic
Nonischemic
History of myocardial infarction
No
Yes

Subgroup

The

m e dic i n e

n engl j med  nejm.org

The New England Journal of Medicine
Downloaded from nejm.org at HENRY FORD HEALTH SYSTEM on December 15, 2020. For personal use only. No other uses without permission.
Copyright © 2020 Massachusetts Medical Society. All rights reserved.

Cardiac Myosin Activation in Systolic Heart Failure

Figure 2 (facing page). Primary Composite Outcome,
According to Prespecified Subgroup.
Shown is the primary outcome of the trial, a composite
of a heart-failure event or cardiovascular death, according to baseline values in subgroups that were prespecified in the protocol. Patients with atrial fibrillation or
flutter at screening were not included in the analysis of
NT-proBNP at baseline. Race or ethnic group were reported by the patients. ACE denotes angiotensin-converting enzyme, ARB angiotensin-receptor blocker,
ARN angiotensin receptor–neprilysin, BP blood pressure, CRT cardiac-resynchronization therapy, eGFR estimated glomerular filtration rate, ICD implantable cardioverter–defibrillator, LVEF left ventricular ejection
fraction, MRA mineralocorticoid-receptor antagonist,
NT-proBNP N-terminal pro–B-type natriuretic peptide,
and NYHA New York Heart Association.

which included all the patients who had undergone randomization except for 24 patients from
a single site who were excluded on the basis of
Good Clinical Practice violations. We evaluated
time-to-event data using Kaplan–Meier estimates
and Cox proportional-hazards models with baseline hazards stratified according to the randomization setting (inpatient or outpatient) and geographic region and with the trial group and the
baseline estimated GFR as covariates. The mean
differences in the change in the KCCQ total symptom score from baseline to week 24 were estimated
with the use of mixed models fit within the randomization setting, with each model containing
fixed effects for the baseline total symptom
score, geographic region, baseline estimated GFR,
scheduled visit (week 12 or week 24), trial group,
and the interaction between trial group and scheduled visit and an unstructured covariance matrix
for repeated measures across visits. A joint omnibus F-test of a treatment difference within at least
one subset of trial patients (inpatients or outpatients) was used to test the treatment effect for
the KCCQ total symptom score.
The prespecified safety analyses included serious adverse events, adverse events associated
with the discontinuation of omecamtiv mecarbil
or placebo, and adverse events of interest (i.e., ventricular arrhythmias leading to treatment and
positively adjudicated major cardiac ischemic
events that included myocardial infarction, hospitalization for unstable angina, and coronary
revascularization). The safety analyses were performed in patients who had undergone randomization and received at least one dose of omecam-

tiv mecarbil or placebo, with the exclusion of the
same 24 patients who had been excluded from
the full analysis set. All analyses were performed
with the use of SAS software, version 9.4 (SAS
Institute).

R e sult s
Patients

From January 6, 2017, to July 9, 2019, a total of
11,121 patients underwent screening at 945 sites
in 35 countries. Of these patients, 8256 underwent randomization. After 24 patients were excluded because of Good Clinical Practice violations, 4120 patients were assigned to receive
omecamtiv mecarbil and 4112 to receive placebo
(Fig. S3). The characteristics of the patients at baseline were well balanced in the two trial groups
(Table 1 and Tables S3 and S4).11 At week 12,
among the patients who were assigned to receive
omecamtiv mecarbil twice daily, 1192 patients
(28.9%) were receiving the 25-mg dose, 559 (13.6%)
the 37.5-mg dose, and 1961 (47.6%) the 50-mg
dose; the remaining 408 patients (9.9%) were not
included in this analysis owing to discontinuation, missing study-visit data, or other reasons.
The overall median duration of follow-up was
21.8 months (interquartile range, 15.4 to 28.6).
A total of 41 patients in the omecamtiv mecarbil
group and 50 patients in the placebo group discontinued participation before the end of the
trial on August 7, 2020. At that time, 16 patients
had unknown vital status.
Outcomes

The primary outcome of a first heart-failure
event or death from cardiovascular causes occurred in 1523 of 4120 patients (37.0%) in the
omecamtiv mecarbil group and in 1607 of 4112
patients (39.1%) in the placebo group (hazard
ratio, 0.92; 95% confidence interval [CI], 0.86 to
0.99; P = 0.03) (Fig. 1A and Table 2). The effect
of omecamtiv mecarbil was generally consistent
across most prespecified subgroups, with the
exception of a possible interaction between trial
group and ejection fraction at baseline (Fig. 2).
The secondary outcome of death from cardiovascular causes occurred in 808 patients (19.6%)
in the omecamtiv mecarbil group and in 798 patients (19.4%) in the placebo group (hazard ratio,
1.01; 95% CI, 0.92 to 1.11; P = 0.86) (Fig. 1B and
Table 2). In the prespecified analysis of the
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Table 3. Laboratory Measures and Safety Outcomes.*
Omecamtiv
Mecarbil
(N = 4110)

Placebo
(N = 4101)

Relative Risk
or Difference
(95% CI)†

At wk 24

1.4±15.3

1.5±15.6

−0.1 (−0.9 to 0.6)

At wk 48

2.0±16.1

1.9±16.0

0.2 (−0.6 to 1.0)

At wk 24

−2.1±12.6

−0.5±12.8

−1.6 (−2.2 to −1.0)

At wk 48

−2.0±13.1

−0.2±13.2

−1.8 (−2.4 to −1.1)

Variable
Change from baseline in vital signs and laboratory measures
Systolic blood pressure — mm Hg

Heart rate — beats/min

Potassium – mmol/liter
At wk 24

−0.01±0.57

−0.01±0.57

0.00 (−0.03 to 0.03)

At wk 48

−0.03±0.59

−0.02±0.58

−0.01 (−0.04 to 0.02)

At wk 24

0.03±0.33

0.02±0.32

0.01 (−0.01 to 0.02)

At wk 48

0.06±0.39

0.05±0.38

0.01 (−0.01 to 0.03)

−251 (−1180 to 295)

−180 (−915 to 441)

0.90 (0.86 to 0.94)

At wk 24

4 (−2 to 21)

0 (−9 to 8)

4 (3 to 5)

At wk 48

2 (−4 to 18)

0 (−9 to 8)

2 (1 to 3)

Creatinine — mg/dl

Median NT-proBNP (IQR) — pg/ml‡
At wk 24
Median cardiac troponin I (IQR) — ng/liter

Safety outcomes — no. (%)§
Discontinuation because of adverse event

371 (9.0)

382 (9.3)

0.97 (0.85 to 1.11)

2373 (57.7)

2435 (59.4)

0.97 (0.94 to 1.01)

Ventricular tachyarrhythmia

290 (7.1)

304 (7.4)

0.95 (0.82 to 1.11)

Torsades de pointes or QT prolongation

176 (4.3)

195 (4.8)

0.90 (0.74 to 1.10)

Serious adverse ventricular arrhythmia leading to treatment

119 (2.9)

127 (3.1)

0.93 (0.73 to 1.20)

200 (4.9)

188 (4.6)

1.06 (0.87 to 1.29)

122 (3.0)

118 (2.9)

—

Serious adverse event
Adverse event of interest

Adjudicated major cardiac ischemic event
Myocardial infarction
Hospitalization for unstable angina
Coronary revascularization
Adjudicated stroke

25 (0.6)

12 (0.3)

—

115 (2.8)

117 (2.9)

—

76 (1.8)

112 (2.7)

0.68 (0.51 to 0.91)

*	Plus–minus values are means ±SD. To convert the values for potassium to milligrams per deciliter, divide by 0.2558. To convert the values
for creatinine to micromoles per liter, multiply by 88.4.
†	The data are reported as relative risk for all safety outcomes.
‡	For the NT-proBNP value, the between-group difference is the geometric mean ratio as determined by the exponentiation of the change
from baseline in log-transformed values from a mixed model containing the log baseline value, geographic region, baseline eGFR, scheduled visit, trial group, and interaction of trial group with the scheduled visit.
§	The safety population included all patients who had undergone randomization and received at least one dose of omecamtiv mecarbil or placebo.

change from baseline to week 24 in the KCCQ
total symptom score according to randomization
setting, the mean between-group difference in
the change (omecamtiv mecarbil minus placebo)
was 2.5 points (95% CI, 0.5 to 4.5) among inpa8

tients and −0.5 (−1.4 to 0.5) among outpatients
(P = 0.03 by joint omnibus F-testing). The combined P value for these comparisons did not meet
the significance threshold of 0.002, according to
the testing procedure for multiplicity control.
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A first hospitalization for heart failure occurred in 1142 patients (27.7%) in the omecamtiv
mecarbil group and in 1179 (28.7%) in the placebo group (hazard ratio, 0.95; 95% CI, 0.87 to
1.03); death from any cause occurred in 1067 patients (25.9%) and 1065 patients (25.9%), respectively (hazard ratio, 1.00; 95% CI, 0.92 to 1.09)
(Table 2 and Figs. S4 and S5). The exploratory
outcome of a first heart-failure event occurred in
1177 patients (28.6%) in the omecamtiv mecarbil group and in 1236 (30.1%) in the placebo
group (hazard ratio, 0.93; 95% CI, 0.86 to 1.00)
(Table 2 and Fig. S6). Sensitivity analyses for
competing risks, potentially informative data
censoring, and missing data regarding the KCCQ
total symptom score because of death produced
similar results to those of the primary analyses
(Tables S5 through S8).
Other outcomes of interest included the effects of omecamtiv mecarbil on vital signs and
selected laboratory values (Table 3). There was
no difference in the change in systolic blood
pressure between baseline and 24 or 48 weeks
between the omecamtiv mecarbil group and the
placebo group; the heart rate was slightly lower
in the omecamtiv mecarbil group than in the
placebo group at the two time points. The change
from baseline in the NT-proBNP level at week 24
was 10% lower (95% CI, 6 to 14) in the omecamtiv mecarbil group than in the placebo group.
Safety

In the safety-analysis set, omecamtiv mecarbil
was discontinued in 847 of 4110 patients (20.6%)
and placebo in 897 of 4101 patients (21.9%). An
adverse event was the reason for discontinuation
in 371 patients (9.0%) in the omecamtiv mecarbil group and 382 (9.3%) in the placebo group.
The trial agent was withheld because of concern
of active myocardial infarction or ischemia in
103 patients in the omecamtiv mecarbil group
and in 101 patients in the placebo group.
Patients in the two groups had no change in
potassium or creatinine levels during the course
of the trial. The median change from baseline in
the level of cardiac troponin I at week 24 was 4 ng
per liter higher in the omecamtiv mecarbil group
than that in the placebo group, according to results on the Siemens ADVIA Centaur Ultra Troponin I assay (lower limit of detection, 6 ng per liter;
upper reference limit, 40 ng per liter).
Adjudicated major cardiac ischemic events

occurred in 200 patients (4.9%) in the omecamtiv
mecarbil group and in 188 (4.6%) in the placebo
group; among these patients, myocardial infarction accounted for 122 events (3.0%) and 118
events (2.9%), respectively (Fig. S7). Ventricular
arrhythmic events occurred at a similar rate in
the two groups. Additional adverse-event data are
provided in Tables S9 and S10.

Discussion
In this randomized, placebo-controlled trial involving patients with heart failure and a reduced
ejection fraction receiving guideline-based pharmacologic and device therapy, those in the
omecamtiv mecarbil group had an 8% lower
relative risk (absolute difference, 2.1 percentage
points) of the composite primary outcome of a
heart-failure event or death from cardiovascular
causes than those in the placebo group. This
effect was observed without evidence of an increase in the risk of myocardial ischemic events,
ventricular arrhythmias, or death from cardiovascular causes or any cause.
The modest but significant lowering of the
incidence of the primary outcome was observed
across a broad range of both inpatients and outpatients,11 including those with moderate or severe heart-failure symptoms and a reduced ejection fraction, systolic blood pressure, and renal
function. The benefit was consistent across most
subgroups, but a possible heterogeneity of effect
was suggested by a potentially greater treatment
effect in patients with an ejection fraction of 28%
or less than in those with an ejection fraction of
more than 28%. Although subgroup analyses
have inherent limitations, potential differences
in benefit according to ejection fraction are biologically plausible, since omecamtiv mecarbil specifically increases cardiac performance.9,16 These
findings support the hypothesis that improving
cardiac function by selectively targeting the cardiac sarcomere with omecamtiv mecarbil can improve clinical outcomes.
This trial did not show that omecamtiv mecarbil improved any of the secondary outcomes.
The lack of effect on death from either cardiovascular causes or any cause is surprising, given
the prior evidence with omecamtiv mecarbil of
improvements in left ventricular volumes and
function, as well as decreases in heart rate and
NT-proBNP in the Chronic Oral Study of Myosin
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Activation to Increase Contractility in Heart Failure (COSMIC-HF)9 and the reduced heart rate
and NT-proBNP level observed in GALACTIC-HF.
A prior meta-analysis suggested that treatments
that reduce ventricular volumes and increase the
ejection fraction are likely to reduce mortality.17
Two meta-analyses of heart-failure trials showed
no significant correlation between therapy-induced
changes in the NT-proBNP level and mortality,18,19
but in one of these meta-analyses, a relationship
between a decrease in the NT-proBNP level and
a reduction in heart-failure hospitalizations was
observed.19 In our trial, the inpatients at the time
of enrollment had a higher burden of symptoms
than those enrolled as outpatients, as suggested
by their worse KCCQ total symptom score at
baseline. However, according to the prespecified
testing procedure, there was no significant difference between the omecamtiv mecarbil group
and the placebo group among either inpatients
or outpatients.20
The identification of medicines that increase
cardiac performance has been a goal of heartfailure therapeutics for more than a century, yet
the drugs that have been developed have consistently increased the incidence of myocardial
ischemia, ventricular arrhythmias, or death1,10 because of their mechanisms of increasing the magnitude of intracellular calcium transients in cardio
myocytes. As a selective cardiac myosin activator,
omecamtiv mecarbil has no effect on these calcium transients,3 and in GALACTIC-HF, the incidences of myocardial ischemia, ventricular arrhythmias, and death were similar in the two
trial groups with almost 7500 patient-years of
follow-up. These findings suggest that despite
the small increase in plasma levels of troponin

of
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that have been noted in some trials8,9 and in the
current trial, treatment with omecamtiv mecarbil
did not increase the risk of these clinical adverse
effects. In addition, no detrimental effects of
omecamtiv mecarbil were detected with respect
to blood pressure, heart rate, and creatinine or
potassium levels.
Our trial has some limitations. It excluded
patients over the age of 85 years and those with
a clinically unstable condition. The underrepresentation of racial groups and women in clinical
trials is a continuing concern.21 Only 7% of the
patients reported their race as Black, although
the number of Black patients was larger than
those in many previous heart-failure trials. Only
approximately 21% of the patients were women,
a percentage that is consistent with findings in
other trials involving patients with heart failure
and a reduced ejection fraction. Although the
background therapy was generally excellent and
more than 19% of the patients were receiving
sacubitril–valsartan at baseline, the compelling
results from recent trials of sodium–glucose cotransporter 2 inhibitors22,23 were not available
until after GALACTIC-HF had completed enrollment, which limited the use of these drugs to
only 2.6% of the patients.
Our trial showed that among patients with
heart failure and a reduced ejection fraction,
those who received omecamtiv mecarbil had a
lower risk of a composite of heart-failure events
and cardiovascular death than those who received
placebo.
Supported by Amgen, Cytokinetics, and Servier.
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